14. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al (2013) Three-year
efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib
with best available therapy for myelofibrosis. Blood 122(25):4047–4053.
15. Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, et al (2020) Primary
analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib
in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 189(5):888-903.